Examining to aid CureVac with experimental COVID-19 vaccine: Bayer CEO

Published On 2021-01-19 04:30 GMT   |   Update On 2021-01-19 04:30 GMT

Berlin: German pharmaceutical giant Bayer is examining whether it can help CureVac to produce its experimental COVID-19 vaccine, its chief executive was quoted as saying on Sunday.Though inoculation campaigns have started around the world using various COVID-19 vaccines, many countries say their ability to get shots into arms is being limited by lower than expected supplies owing to a shortage...

Login or Register to read the full article

Berlin: German pharmaceutical giant Bayer is examining whether it can help CureVac to produce its experimental COVID-19 vaccine, its chief executive was quoted as saying on Sunday.

Though inoculation campaigns have started around the world using various COVID-19 vaccines, many countries say their ability to get shots into arms is being limited by lower than expected supplies owing to a shortage of production.

"We are prepared to pull out all the stops for this," Werner Baumann told the Welt am Sonntag newspaper.

"This is not primarily about financial considerations but about making the vaccine available as quickly as possible."

Bayer agreed this month to help fellow German company CureVac with development of its COVID-19 vaccine candidate, which is in late-stage clinical trials and has not yet been approved.

Baumann said the drugmaker was "intensively examining" whether to expand its co-operation to include manufacturing the vaccine for CureVac.

Read also: Bayer, Arogya Finance collaborate to introduce Eylea Easy Pay Program in India

"With our production network in Germany and the USA and the corresponding lead time, we would in principle be in a position to produce vaccine in larger quantities," he said.

On Friday U.S. drugmaker Pfizer said there would be a temporary slowdown of shipments of the vaccine it developed with German partner BioNTech, citing changes in manufacturing processes to boost output.

Read also: Bayer gets USFDA Priority Review for finerenone for type 2 diabetes, CKD





Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News